Surgery Today

, Volume 49, Issue 2, pp 150–157 | Cite as

Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma

  • Takanori Kurogochi
  • Michitaka Honda
  • Kotaro Yamashita
  • Masaru Hayami
  • Akihiko Okamura
  • Yu Imamura
  • Shinji Mine
  • Masayuki WatanabeEmail author
Original Article



Neoadjuvant chemotherapy (NAC) followed by esophagectomy has become a standard treatment for esophageal squamous cancer (ESCC) in Japan. We used propensity-matching analysis to clarify the safety and efficacy of NAC in daily clinical practice.


We reviewed the medical records of 335 patients with clinical Stage II/III ESCC diagnosed between 2007 and 2012, including 191 who received preoperative NAC (NAC group) and 144 treated by upfront surgery (US group). After propensity score matching, there were 118 patients in each group. We compared the postoperative complications and long-term outcomes between the groups.


Seven patients in the NAC group underwent replacement therapy. Complications occurred in 76 (68.5%) and 76 (64.4%) patients in NAC and US groups, respectively (p = 0.51), and severe complications occurred in 17 (22.4%) and 30 (39.5%) patients, respectively (p = 0.057). One (0.8%) and three patients (2.5%) from the US group died within 30 days and 90 days after surgery, respectively, but none of the patients from the NAC group died within the same period. The 5-year survival rate was 54.9% in the NAC group and 41.2% in the US group (p = 0.024).


NAC is a safe and effective treatment to improve prognosis in the clinical setting.


Neoadjuvant chemotherapy Esophageal cancer Complications Daily clinical practice 


Compliance with ethical standards

Conflict of interest

We have no conflicts of interest to disclose.


  1. 1.
    Ando N, Kato H, Igaki H, Shinoda M, Ozawa S, Shimizu H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68–74.CrossRefGoogle Scholar
  2. 2.
    Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, et al. Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan Esophageal Society. Esophagus. 2015;12:1–30.CrossRefGoogle Scholar
  3. 3.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefGoogle Scholar
  4. 4.
    Coupland VH, Allum W, Blazeby JM, Mendall MA, Hardwick RH, Linklater KM, et al. Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer. 2012;12:11.CrossRefGoogle Scholar
  5. 5.
    Pandeya N, Olsen CM, Whiteman DC. Sex differences in the proportion of esophageal squamous cell carcinoma cases attributable to tobacco smoking and alcohol consumption. Cancer Epidemiol. 2013;37:579–84.CrossRefGoogle Scholar
  6. 6.
    Vioque J, Barber X, Bolumar F, Porta M, Santibanez M, de la Hera MG, et al. Esophageal cancer risk by type of alcohol drinking and smoking: a case–control study in Spain. BMC Cancer. 2008;8:221.CrossRefGoogle Scholar
  7. 7.
    Lee CH, Wu DC, Lee JM, Wu IC, Goan YG, Kao EL, et al. Carcinogenetic impact of alcohol intake on squamous cell carcinoma risk of the oesophagus in relation to tobacco smoking. Eur J Cancer. 2007;43(7):1188–99.CrossRefGoogle Scholar
  8. 8.
    Robert NJ, Goertz HP, Chopra P, Jiao X, Yoo B, Patt D, et al. HER2-positive metastatic breast cancer patients receiving Pertuzumab in a community oncology practice setting: treatment patterns and outcomes. Drugs Real World Outcomes. 2017;4:1–7.CrossRefGoogle Scholar
  9. 9.
    Salas-Vega S, Iliopoulos O, Mossialos E. Assessment of overall survival, quality of life, and safety benefits associated with new cancer medicines. JAMA Oncol. 2017;3:382–90.CrossRefGoogle Scholar
  10. 10.
    Klevebro F, Lindblad M, Johansson J, Lundell L, Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. Br J Surg. 2016;103(13):1864–73.CrossRefGoogle Scholar
  11. 11.
    Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, et al. Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32:2416–22.CrossRefGoogle Scholar
  12. 12.
    Surgical resection with. or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727–33.CrossRefGoogle Scholar
  13. 13.
    Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.CrossRefGoogle Scholar
  14. 14.
    Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.CrossRefGoogle Scholar
  15. 15.
    Sobin LHMKG, Wittekind C. TNM classification of malignant tumours. 7th Edn. Hoboken:Wiley-Blackwell; 2011.Google Scholar
  16. 16.
    Japan Esophageal Society. Japanese classification of esophageal cancer. Part I esophagus. 11th edn, 2017;14:1–36.Google Scholar
  17. 17.
    Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefGoogle Scholar
  18. 18.
    Rubin PRRDB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–5.CrossRefGoogle Scholar
  19. 19.
    Kataoka K, Nakamura K, Mizusawa J, Fukuda H, Igaki H, Ozawa S, et al. Variations in survival and perioperative complications between hospitals based on data from two phase III clinical trials for oesophageal cancer. Br J Surg. 2015;102:1088–96.CrossRefGoogle Scholar
  20. 20.
    Kataoka K, Takeuchi H, Mizusawa J, Igaki H, Ogawa S, Abe T, et al. Prognostic impact of postoperative morbidity after esophagectomy for esophageal cancer: exploratory analysis of JCOG9907. Ann Surg. 2017;265:1152–7.CrossRefGoogle Scholar
  21. 21.
    Yoshida N, Baba Y, Hiyoshi Y, Shigaki H, Kurashige J, Sakamoto Y, et al. Duration of smoking cessation and postoperative morbidity after esophagectomy for esophageal cancer: How long should patients stop smoking before surgery? World J Surg. 2016;40:142–7.CrossRefGoogle Scholar
  22. 22.
    Cerantola Y, Hubner M, Grass F, Demartines N, Schäfer M. Immunonutrition in gastrointestinal surgery. Br J Surg. 2011;98:37–48.CrossRefGoogle Scholar
  23. 23.
    Mabvuure NT, Roman A, Khan OA. Enteral immunonutrition versus standard enteral nutrition for patients undergoing oesophagogastric resection for cancer. Int J Surg. 2013;11:122–7.24.CrossRefGoogle Scholar
  24. 24.
    Engelman E, Maeyens C. Effect of preoperative single-dose corticosteroid administration on postoperative morbidity following esophagectomy. J Gastrointest Surg. 2010;14(5):788–804.CrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  • Takanori Kurogochi
    • 1
  • Michitaka Honda
    • 1
    • 2
  • Kotaro Yamashita
    • 1
  • Masaru Hayami
    • 1
  • Akihiko Okamura
    • 1
  • Yu Imamura
    • 1
  • Shinji Mine
    • 1
  • Masayuki Watanabe
    • 1
    Email author
  1. 1.Department of Gastroenterological SurgeryThe Cancer Institute Hospital of Japanese Foundation for Cancer ResearchTokyoJapan
  2. 2.Department of Minimally Invasive Surgical and Medical OncologyFukushima Medical UniversityFukushimaJapan

Personalised recommendations